Drawing for CROMSOURCE

USPTO serial 79123918

CROMSOURCE

Reviewed by CopyMark Law Group

Reg. 4445694Status 706Registered
Filing date
Status date
Registration date
Dec 10, 2013
Examiner
SHANAHAN, PATRICK
Law office
Historical data usage

What this means

This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.

Need help with CROMSOURCE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

James J. Bitetto

James J. Bitetto Tutunjian & Bitetto, P.C.401 Broadhollow Road, Suite 402Melville, NY 11747United States

Goods and services

ClassDescriptionStatusFirst use
009[ Calculating machines; Computers; ] Information processing equipment and electronic processors, namely, electronic data processing apparatus; Computer software platforms for the collection, management and monitoring of data in studies and clinical and pharmaceutical trials, medical and biomedical researchesACTIVE—
035[ Advertising; Business management; Business administration assistance; Providing office functions; ] Administrative and managerial activities in research and clinical, medical, biomedical and pharmaceutical trials, namely, providing information management services, management and compilation of computerized databases in the field of clinical trials for business purposes; Management of clinical data, namely, providing the services of organizing and managing the results of clinical, medical, biomedical and pharmaceutical trials for human and veterinary use; Providing business information and advice to others regarding the selection of equipment, medical instruments and medical, biomedical and pharmaceutical products to be purchased, leased, rented or hired; Business consultancy for commercial purposes in connection with the approval of medicines and medicinal products, equipment and instruments, business management and product commercialization; Business consulting services in the nature of reviewing the results of business feasibility studies and statistical studies in the field of clinical researches; Preparation of business reports on the development and use of medical, biomedical and pharmaceutical products; Management of clinical data for clinical, medical, and pharmaceutical diagnosis, namely, providing the services of organizing and managing clinical, medical and pharmaceutical results for human and veterinary use; Services of management and compilation of computer databases in the field of studies and clinical, medical, biomedical and pharmaceutical trials; Services of search and selection of personnel specialized in the field of clinical medical, biomedical and pharmaceutical research; Services of recruitment and management of patients for participations in clinical studies for testing medicines and other products in the biomedical fieldACTIVE—
041Education services, namely, classes, seminars, workshops, in the field of clinical, medical, biomedical, pharmaceutical and biostatics fields; Training on techniques and technologies in the clinical, medical, biomedical, pharmaceutical and biostatistics fieldACTIVE—
042Scientific and technological services, namely, scientific research in the medical, biomedical, chemical, biochemical, biological and bacteriological fields; Industrial research and analysis in the fields of medical, biomedical, chemical, biochemical, biological and bacteriological products; Design and development of computer hardware and software; Scientific and technological research, namely, conducting clinical trials for others in the clinical, medical, biomedical and pharmaceutical field; Remote monitoring of the electrical and electronic function and use of clinical, medical and biomedical equipment; Computer programming services for the creation of contents for virtual worlds and three-dimensional platforms in the field of clinical medical, biomedical and pharmaceutical research; Technical consultancy for the purpose of ascertaining and certifying that applicable standards are complied with in the field of medical, biomedical, pharmaceutical research and clinical trialsACTIVE—
044Medical services; consultancy and information services relating to pharmaceutical productsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Sep 19, 2025INNPPARTIAL INVALIDATION PROCESSED BY THE IB—
Aug 31, 2025INPSPARTIAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Aug 30, 2025INPCINVALIDATION PROCESSED—
May 11, 2025INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Sep 11, 2024NA71NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED—
Sep 11, 202471AGREGISTERED-SEC.71 ACCEPTED—
Sep 9, 2024APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Dec 11, 2023ES71TEAS SECTION 71 RECEIVED—
Dec 10, 2022REM4COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED—
Apr 15, 2022RNWLINTERNATIONAL REGISTRATION RENEWED—
Feb 21, 2020NA75NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED—
Feb 21, 2020C75AREGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.—
Jan 29, 2020APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Dec 9, 2019ES75TEAS SECTION 71 & 15 RECEIVED—
Dec 10, 2018REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Dec 18, 2014ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Mar 28, 2014FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Mar 10, 2014FICSFINAL DISPOSITION NOTICE SENT TO IB—
Mar 10, 2014FIMPFINAL DISPOSITION PROCESSED—
Mar 10, 2014FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Dec 10, 2013R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 24, 2013NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Sep 24, 2013PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 23, 2013GPNXNOTIFICATION PROCESSED BY IB—
Sep 4, 2013OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Sep 4, 2013OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Sep 4, 2013NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Aug 17, 2013PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Aug 15, 2013ALIEASSIGNED TO LIE—
Aug 2, 2013CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 1, 2013TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 31, 2013CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 31, 2013TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 27, 2013RFNPREFUSAL PROCESSED BY IB—
Feb 7, 2013RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Feb 7, 2013RFRRREFUSAL PROCESSED BY MPU—
Feb 7, 2013RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Feb 6, 2013CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jan 29, 2013MAFRAPPLICATION FILING RECEIPT MAILED—
Jan 25, 2013DOCKASSIGNED TO EXAMINER—
Jan 25, 2013NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 17, 2013REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance